Compare Bristol-Myers Squibb Co (BMY) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs State Street Technology Select Sector SPDR ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.33 (market cap $116.30B), while State Street Technology Select Sector SPDR ETF trades at $181.58. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals.
| BMY | XLK | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $198.21 |
52-Week Low | $42.60 | $127.49 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
XLK trades at $181.28, down 2.43% on the day, with technical indicators showing a bearish moving average trend but neutral oscillators. The ETF has delivered strong year-to-date performance, gaining 33% as of July 2, 2026 (ETF Trends), driven by technology sector leadership. Recent news highlights robust Q2 earnings expectations and institutional inflows into tech ETFs.
Outlook remains cautiously optimistic given sector momentum and earnings growth projections, though risks include market concentration and valuation concerns. The neutral technical signal suggests near-term consolidation, while fundamental strength in tech supports long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
